{"type":"trials","record":{"id":31153,"source_id":"clinicaltrials-gov","external_id":"NCT07467512","title":"Exercise for an Aging Liver (EXALIVER)","brief_summary":"The goal of this clinical trial is to learn how physical exercise affects liver health in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or at-risk metabolic dysfunction-associated steatohepatitis (MASH); comparing responses between middle-aged adults (40-60 years old) and older adults (70 years and older) of any sex, as well as between participants with low-risk MASLD and high-risk MASH. The main question it aims to answer is: Could an exercise program reduce liver fat, inflammation and fibrosis, regardless of age and disease severity? Researchers will compare 4 different groups: A) older adults with at risk MASH who will exercise B) middle-aged people with at risk MASH who will exercise C) middle-aged people with low-risk MASLD who will exercise D) middle-aged people with low-risk MASLD who will not exercise, receiving usual care. Participants in the exercise groups will take part in a supervised 12-week exercise program that includes both strength and aerobic training, completed twice a week. All participants, including those receiving usual care, will have health asssessments before and after the 12-week period to measure changes in liver health.","overall_status":"Not Yet Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Consorcio Centro de Investigación Biomédica en Red (CIBER)","enrollment":40,"countries":["Spain"],"start_date":"2026-03-01","completion_date":"2027-10-01","last_update_date":"2026-03-12","source_url":"https://clinicaltrials.gov/study/NCT07467512","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:16:21.317971+00:00","last_seen_at":"2026-09-25T07:05:20.248+00:00","metadata":{"sex":"ALL","acronym":"EXALIVER","age_range":"40 Years","comparator":"Middle-age adults with MASLD receiving usual care","organization":"Consorcio Centro de Investigación Biomédica en Red (CIBER)","interventions":["Exercise","Usual Care"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in hepatic fat content — Change from baseline to 12 weeks","Change in liver inflammation and fibrosis — Change from baseline to 12 weeks","Change in liver stiffness — Change from baseline to 12 weeks.","Change in Enhanced Liver Fibrosis (ELF) Score — Change from baseline to 12 weeks","Change in Pro-C3 serum levels — Change from baseline to 12 weeks","Change in NIS4 serum biomarker of liver fibrosis — Change from baseline to 12 weeks","Change in Metabolomics Advanced Steatohepatitis Fibrosis Score (MASEF) — Change from baseline to 12 weeks","Change in visceral adipose tissue — Change from baseline to 12 weeks","Change in pancreatic fat content — Change from baseline to 12 weeks","Change in abdominal subcutaneous adipose tissue — Change from baseline to 12 weeks","Change in abdominal intermuscular fat content — Change from baseline to 12 weeks","Change in abdominal intramuscular fat content — Change from baseline to 12 weeks","Change in abdominal skeletal muscle tissue — Change from baseline to 12 weeks","Change in values of fasting glucose — Change from baseline to 12 weeks","Change in values of HbA1c — Change from baseline to 12 weeks","Change in values of fasting insulin — Change from baseline to 12 weeks","Change in levels of mean glucose (Continuous Glucose Monitoring) — Change from baseline to 12 weeks.","Change in fasting lipid profile — Change from baseline to 12 weeks","Change in alkaline phosphatase — Baseline to 12 weeks","Change in alanine aminotransferase (ALT) — Baseline to 12 weeks"],"design_description":"NON RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","MASH - Metabolic Dysfunction-Associated Steatohepatitis","Liver Fibrosis/NASH","Exercise","Usual Care"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: exercise.","quality_checked_at":"2026-09-25T07:05:30.295959+00:00","duplicate_cluster_key":"id:nct07467512","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-03-01 to 2027-10-01","comparator":"Middle-age adults with MASLD receiving usual care","confidence":"structured-source","population":"ALL · 40 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T07:05:20.281Z","intervention":["Exercise","Usual Care"],"participants":40,"study_design":"NON RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in hepatic fat content — Change from baseline to 12 weeks","Change in liver inflammation and fibrosis — Change from baseline to 12 weeks","Change in liver stiffness — Change from baseline to 12 weeks.","Change in Enhanced Liver Fibrosis (ELF) Score — Change from baseline to 12 weeks","Change in Pro-C3 serum levels — Change from baseline to 12 weeks","Change in NIS4 serum biomarker of liver fibrosis — Change from baseline to 12 weeks","Change in Metabolomics Advanced Steatohepatitis Fibrosis Score (MASEF) — Change from baseline to 12 weeks","Change in visceral adipose tissue — Change from baseline to 12 weeks","Change in pancreatic fat content — Change from baseline to 12 weeks","Change in abdominal subcutaneous adipose tissue — Change from baseline to 12 weeks","Change in abdominal intermuscular fat content — Change from baseline to 12 weeks","Change in abdominal intramuscular fat content — Change from baseline to 12 weeks","Change in abdominal skeletal muscle tissue — Change from baseline to 12 weeks","Change in values of fasting glucose — Change from baseline to 12 weeks","Change in values of HbA1c — Change from baseline to 12 weeks","Change in values of fasting insulin — Change from baseline to 12 weeks","Change in levels of mean glucose (Continuous Glucose Monitoring) — Change from baseline to 12 weeks.","Change in fasting lipid profile — Change from baseline to 12 weeks","Change in alkaline phosphatase — Baseline to 12 weeks","Change in alanine aminotransferase (ALT) — Baseline to 12 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"exercise","is_published":true,"match_reasons":["Title contains controlled term: exercise.","Abstract contains controlled term: exercise.","Source terminology contains: exercise.","Title supplies longevity context: aging.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Exercise","slug":"exercise"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/31153","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}